Chinese drugmakers develop copycat versions of ‘miracle’ weight-loss drug
中国药企争相研发国产版“减肥神药”
Low-cost domestic rivals hope to challenge Novo Nordisk in one of world’s biggest markets for anti-obesity medication
诺和诺德的司美格鲁肽在新一代减肥药市场占据主导地位，但在中国，有数十种使用相同机制的药物正在进行临床试验。
Chinese pharmaceutical companies are developing domestic versions of “miracle” weight-loss drugs as they take on western drugmakers selling anti-obesity medication in one of the world’s biggest markets.
中国制药企业正在研发国产版“减肥神药”，它们要在这个全球最大的抗肥胖药物市场之一与西方制药商展开竞争。
Chinese drug companies hope to compete with the Danish pharma group Novo Nordisk’s pioneering drugs in China, which has the world’s largest overweight and diabetic population. If successful, they could also potentially offer a cheaper alternative in the west.
中国是世界上超重和糖尿病人口最多的国家。中国制药企业希望在国内市场与丹麦制药集团诺和诺德(Novo Nordisk)的先锋药物展开竞争。如果成功，它们还可能在西方提供更便宜的替代品。
The new generation of weight-loss drugs form part of a category called glucagon-like peptide-1 agonists or GLP-1s. Novo Nordisk’s semaglutide or Ozempic dominates the market, but dozens using the same mechanism are undergoing clinical trials in China, analysts said.
新一代减肥药属于胰高血糖素样肽-1激动剂，即GLP-1类药物。分析师表示，诺和诺德的司美格鲁肽(semaglutide)——商品名Ozempic——在这类药物的市场上占据主导地位，但在中国，有数十种使用相同机制的药物正在进行临床试验。
